Why Most Clinical Trials Fail Before They Start

And How a Growing Global Feasibility Network Changes That

Clinical trials rarely fail because of science.

They fail because of unrealistic feasibility assumptions.

Overestimated recruitment. Under performing sites. Delayed activation. Amendments that drain budgets.

And every month lost is lost patent lifetime.

The Real Risk: Poor Site Selection

Sponsors and CROs still rely heavily on:

• Historical relationships

• Email-based feasibility surveys

• Self-reported recruitment optimism

• Fragmented spreadsheets

This creates false confidence early — and operational stress later.

Feasibility is not administration.It is strategic risk control.

A Structural Shift: A Growing Global Site Network

The number of qualified, GCP-experienced sites registered on EasyFeasibility© continues to grow internationally.

This changes the dynamic of study planning.

Instead of reactive site outreach, sponsors gain:

• Structured, standardized digital questionnaires

• Transparent patient pool estimates

• Documented compliance credentials

• Centralized data evaluation

The difference is not cosmetic. It reduces planning uncertainty.

From Feasibility to Execution — Without System Breaks

EasyFeasibility© is fully integrated within the EasyClin® Suite. That means:

• Site documentation aligns automatically

• No duplicate data entry

• No fragmented systems

The transition from planning to execution becomes seamless.

For sponsors and CROs, this reduces:

• Setup delays

• Operational friction

• Monitoring inefficiencies

And most importantly — risk.

Why Network Size Matters

Each additional qualified site strengthens:

• Geographic flexibility

• Recruitment predictability

• Therapeutic specialization coverage

• Competitive positioning in global trials

For biotech companies, this can mean:

Faster activation. More reliable enrollment. Stronger investor confidence.

For CROs:

Higher-quality feasibility deliverables. Reduced downstream firefighting. Stronger sponsor trust.

The Economic Reality

In clinical development, time equals value.

Delays cost:

• Market opportunity

• Competitive advantage

• Patent lifetime

• Investor confidence

A structured digital feasibility process is one of the highest ROI decisions a sponsor can make early in development.

Because fixing feasibility mistakes later is exponentially more expensive.

Built for Compliance and Scalability

The EasyClin® infrastructure ensures:

• EU-GCP compliance

• GDPR by design

• Role-based access

• Full audit trail

• Secure cloud deployment

This is not an add-on.It is foundational architecture.

The Next Step: Data-Driven Site Intelligence

As the network grows, structured data enables:

• Performance bench-marking

• Early risk detection

• Predictive modeling

Feasibility becomes intelligence — not just screening.

If You Are Planning a Study in 2026

Before sending out the next spreadsheet.

Before activating sites based on optimism.

Before committing to recruitment projections.

Ask:

How confident are we in our feasibility assumptions?

If you would like to explore how structured digital feasibility can reduce risk and improve predictability in your next study, we invite you to schedule a confidential discussion.

👉 Book a demonstration: www.synapcon.net

Or register your site to increase global sponsor visibility.

Structured digital feasibility is becoming the foundation of predictable clinical development.